Cyclin-dependent kinase degraders and methods of use
US12325725B2 · kind B2 · utility
0Cited by
1References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 13, 2019 |
| Grant date | Jun 10, 2025 |
| Priority date | — |
| Expiry date | Feb 13, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07J41/0027
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present application provides compounds of Formula (Ia), or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, which act as protein degradation inducing moieties for one or more of cyclin-dependent kinase 8 (CDK8) and cyclin-dependent kinase 19 (CDK19). The present application also relates to methods for the targeted degradation of CDK8 and/or CDK19 through the use of the compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to CDK8 and/or CDK19 which can be utilized in the treatment of disorders modulated by CDK8 and/or CDK19.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.